Research Focus: Targeting Tropomyosin Receptor Kinases in Cancer
Source: Research Focus: Targeting Tropomyosin Receptor Kinases in Cancer

Module

In this CME-certified module with accompanying downloadable slideset, Todd M. Bauer, MD, provides expert insights on the biologic role of TRK fusions in cancer along with emerging clinical trial data on TRK-targeted therapies across multiple tumor types.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of NTRK gene fusions in the development of cancers and the novel agents inhibiting TRK
  • Describe how TRK fusions occur in diverse cancers and the rationale and process for testing

Topics covered include:

  • Targeting Tropomyosin Receptor Kinases in Cancer
 

Faculty

  • Todd M. Bauer
    MD

Credit Information

  • Release Date:
    April 16, 2018
  • Expiration Date:
    April 15, 2019
  • Physicians:
    maximum of 0.75 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Todd M. Bauer, MD


Associate Director, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that he has received consulting fees from Pfizer.

 

Staff

Rachael M. Andrie, PhD


Associate Managing Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

 

Megan Cartwright, PhD


Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

 

Timothy A. Quill, PhD


Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for oncologists and other healthcare professionals who care for patients with cancer.


Goal

The goal of this activity is to improve participants’ awareness of the potential role of TRK inhibitors in the treatment of adults and children with cancer.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of NTRK gene fusions in the development of cancers and the novel agents inhibiting TRK
  • Describe how TRK fusions occur in diverse cancers and the rationale and process for testing
 

Physician Continuing Medical Education


Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Loxo Oncology.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 16, 2018, through April 15, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.